Who We Are And What We Do?

Many children are living with a rare disease. The complex challenges facing these children and families deserve attention and demand innovative treatment to meet unmet medical needs. However, research in this field is insufficient as government funding goes primarily to common disease areas such as cancer, diabetes, lung disease, HIV, and infectious disease such as COVID 19. Because rare diseases usually impact less than 200,000 people in the United States, funding for research is limited slowing down the understanding and potential cure for these rate diseases. The Childrens Rare Disease Organization, Inc. (the Organization) was created in order to remedy this and fund research of rare diseases impacting children in an effort to find a cure or treatment.

The organization hopes to promote research of rare children’s diseases and fund research labs and organizations, both in the United States and abroad, that focus on rare children’s diseases. Priority will be those challenging diseases with no underlying cause identified. Research progress in these kinds of diseases is extremely behind in the scientific field because of their complexity and unknown causes.

The Organizations Board of Directors is composed of highly educated Ph.Ds. and M.D.s who have the specific credentials and are qualified to evaluate research proposals. Based on the scientific evaluation of the research area of the proposals, the evaluation committee will determine which research studies to fund. All board members have more than 20 years of drug development experience in the manufacturing, nonclinical and clinical areas.


    Audrey Jia, M.D., Ph.D.

    Dr. Jia holds a Master degree in Bioscience Regulatory Affairs from Johns Hopkins University, and a Ph.D. degree in Microbiology and Molecular Genetics from Emory University. Prior to that, Dr. Jia obtained her medical degree from Peking University, and passed USMLE. Dr. Jia has 20 years of combined experience in biologic drug development and regulatory review. Dr. Jia spent 10 years working on biological product research and production in Pfizer, AbbVie and Protein Design Labs Inc. Additionally, Dr. Jia was a full-time senior CMC reviewer for IND/BLA review of biological products in US FDA. She performed numerous IND reviews, BLAs (including post approval reviews), and US/international cGMP pre-approval inspections (PAIs).

      Yan Bai, M.D., Ph.D.

      Dr. Bai holds a Ph.D. degree in Epidemiology from Emory University, and a medical degree from Peking University Health Science Center. He had his post-doc training in Epidemiology from NIH. Dr. Bai has twenty years of experience in pharmacoepidemiology, clinical development, drug safety and cancer research with strong skills in epidemiology strategy, medical safety evaluation and understanding of the US and global pharmacovigilance processes. He is a regulatory expert in clinical oncology and endocrinology, and currently serves as a senior consultant in DataRevive USA LLC. Before that, He worked at Allergan Inc., Vertex Pharmaceuticals, Sanofi-Aventis, and Johnson & Johnson.

        Julia Carrier, Ph.D.

        Dr. Carrier holds a Ph.D. degree in Immunology from Emory University, and a bachelor of science from Peking University Health Science Center. She had her post-doc training in Immunology from Harvard University. Dr. Carrier has twenty years of experience in Immunology, nonclinical PK/PD and toxicology. She has extensive experience in nonclinical studies and study designs in oncology, infectious disease, liver disease, cardiology, and ophthalmology disease. She is a regulatory expert in nonclinical area and currently serves as a lead consultant in DataRevive USA LLC. Before that, she worked at Pfizer Centers for Therapeutic Innovation for many years as nonclinical lead.